• Clarithromycin: A CYP3A Probe for Better Assays

  2026-08-11

  Clarithromycin is a potent CYP3A inhibitor for drug-drug interaction research, but its greatest value comes from disciplined assay interpretation. This guide presents a pathway-centered design strategy using pharmacokinetic controls, solubility-aware handling, and the dabigatran literature as a mechanistic contrast.

• Vitamin D/VDR and Endometrial Decidualization

  2026-08-10

  This study identifies a vitamin D/VDR signaling axis that promotes human endometrial stromal cell decidualization through CYP19 and ESR1 regulation. Its combined use of loss-of-function, gain-of-function, primary-cell validation, and ChIP-qPCR provides a mechanistic framework for studying vitamin D in endometrial receptivity and infertility research.

• Cefepime (BMY-28142) for Infection Research

  2026-08-09

  Cefepime (BMY-28142) supports reproducible bacterial infection models, central nervous system infection research, and resistance-mechanism assays. This practical guide covers stock handling, microdilution design, barrier-model considerations, neurotoxicity controls, and lessons that can be adapted from large-scale cefiderocol surveillance.

• KPT-330 (Selinexor): CRM1 Inhibition Guide

  2026-08-08

  KPT-330, also called Selinexor, is an orally bioavailable selective CRM1/XPO1 inhibitor used in cancer research. Evidence links CRM1 inhibition with nuclear retention of regulatory proteins, apoptosis and cell-cycle effects in cancer models, while a 2026 study extends preclinical investigation to osteoclastogenesis in osteoarthritis.

• SGI-1027–Everolimus in Renal Cancer

  2026-08-07

  This study identifies SGI-1027 as a methuosis inducer in renal cancer and shows that it cooperates with everolimus to suppress tumor-cell growth, migration, and invasion. The proposed mechanism links lysosomal membrane permeability with apoptosis and GSDME-dependent pyroptosis, providing a framework for investigating lysosome-centered strategies against everolimus-resistant renal cell carcinoma.

• SB-505124 Hydrochloride: Precision Inhibition in Fibrosis Mo

  2026-08-07

  SB-505124 hydrochloride enables high-fidelity dissection of TGF-β/activin signaling in fibrosis and mechanobiology research, with robust selectivity and non-cytotoxic delivery. Its validated performance in complex models, like glaucoma filtration surgery and advanced cancer mechanotransduction assays, sets a new standard for reproducibility and insight.

• Ceramide-Driven Lipid Remodeling in Fish Nodavirus Infection

  2026-08-06

  This study employs lipidomics to unravel the pivotal pro-viral role of ceramides during red-spotted grouper nervous necrosis virus (RGNNV) infection. The findings highlight ceramide accumulation and autophagy as central mechanisms facilitating viral replication, offering new perspectives for experimental strategies in aquatic virology and cellular lipid research.

• Fucoidan: Protocol Innovations in Breast Cancer Research

  2026-08-06

  Fucoidan, a sulfated α-L-fucan from brown seaweed, delivers selective cytotoxicity and novel mechanistic targeting in breast cancer models. This article translates the latest reference study and validated preclinical workflows into actionable protocols and troubleshooting strategies for oncology researchers.

• METTL14–DHRS4-AS1/miR-206/A3AR Axis Modulates UC Inflammatio

  2026-08-05

  A recent study elucidates how METTL14-mediated m6A methylation regulates inflammation in ulcerative colitis by modulating the lncRNA DHRS4-AS1/miR-206/A3AR axis. These insights clarify epigenetic mechanisms in UC pathogenesis and suggest new therapeutic targets for inflammatory bowel disease.

• Gemcitabine: DNA Synthesis Inhibitor for Cancer Research

  2026-08-05

  Gemcitabine is a potent DNA synthesis inhibitor, widely used in cancer research for its anti-tumor and pro-apoptotic effects. It disrupts DNA replication, activates checkpoint pathways, and has measurable efficacy in both in vitro and in vivo models. This review details its mechanisms, benchmarked applications, and protocol integration.

• Targeting Anti-Apoptotic BCL-2 Proteins in Glioblastoma: BH3

  2026-08-04

  This article examines how increased apoptotic priming in glioblastoma (GBM) enables effective therapeutic targeting through BH3-mimetic inhibitors, as shown by Koessinger et al. (2022). The study reveals that GBM’s dependence on BCL-xL and MCL-1 for survival creates a vulnerability that can be exploited by sequential inhibition, providing a rationale for translational research on BCL-2 family inhibitors in solid tumors.

• AP1903: FKBP-Binding Ligand for Precision Cell Ablation Work

  2026-08-04

  AP1903 from APExBIO sets the benchmark for nanomolar-precision conditional cell ablation and controlled protein activation in multiplexed biological systems. Its unique potency and reliability underpin high-throughput functional genomics, apoptosis pathway research, and in vivo cell targeting workflows.

• SD 169 (indole-5-carboxamide): Advancing p38 MAPK Pathway Re

  2026-08-03

  SD 169 (indole-5-carboxamide) delivers dual-action control over p38α/β MAPKs, enabling robust, reproducible results across inflammation, diabetes, and axonal regeneration models. Its unique mechanism—combining ATP-competitive inhibition and enhanced kinase dephosphorylation—translates into superior pathway modulation for both standard and next-generation assays.

• Hematoxylin and Eosin Staining Kit: Technical Workflow Guide

  2026-08-03

  The Hematoxylin and Eosin Staining Kit (SKU K1142) delivers ready-to-use reagents for reliable tissue morphology visualization in research, streamlining nuclear and cytoplasmic staining of paraffin and frozen sections. Designed for laboratory workflows, it minimizes user error and protocol variability. This product is strictly for scientific research and not for clinical diagnosis.

• M344 as a Histone Deacetylase Inhibitor in Neuroblastoma Wor

  2026-08-02

  M344 stands out as a potent, cell-permeable histone deacetylase inhibitor for cancer and epigenetics research, enabling precise modulation of gene expression and tumor phenotypes. This article details optimized workflows, experimental troubleshooting, and unique translational use-cases grounded in the latest neuroblastoma research.

446 records 8/30 page Previous Next First page 上5页 678910 下5页 Last page